Quantum-Si downgraded by Canaccord Genuity with a new price target
$QSI
Industrial Machinery/Components
Industrials
Canaccord Genuity downgraded Quantum-Si from Buy to Hold and set a new price target of $2.00 from $3.50 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/7/2025 | $3.75 | Buy | Alliance Global Partners |
| 12/8/2023 | $3.00 | Buy | H.C. Wainwright |
| 9/25/2023 | $3.50 → $2.00 | Buy → Hold | Canaccord Genuity |
| 10/20/2021 | $13.00 | Buy | Canaccord Genuity |
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, announces the start of shipments for its latest benchtop sequencer, Platinum® Pro. This groundbreaking instrument offers protein analysis with single-molecule precision, aiming to make Next-Gen Protein Sequencing™ more accessible to laboratories worldwide. Platinum Pro delivers a comprehensive solution for sequencing and analyzing proteins through a simple, integrated workflow. Building upon the foundation of innovation established by the original Platinum, the new system introduces advanced features tailored to the evolving needs of researchers and biopharmaceutical customers. Key
Validate multi-omics findings at the single-molecule level with Next-Gen Protein Sequencing™ Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, announces participation in an upcoming DNAnexus webinar focused on the role of proteomics in multi-omics research. This discussion will explore how the integration of proteomics data with other omics datasets is driving new discoveries in disease research, including cancer. When: March 25, 2025, at 8 a.m. PT/11 a.m. ET Attendees will learn about: The growing impact of proteomics in multi-omics analysis Applications for cancer and other disease research Technologies and strategies fo
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced that the Compensation Committee of Quantum-Si's Board of Directors has granted 20,833 restricted stock units ("RSUs") to new employees under the Company's previously adopted Quantum-Si Incorporated 2023 Inducement Equity Incentive Plan, as amended (the "2023 Inducement Plan"). The RSUs were granted as an inducement material to the new employees becoming an employee of Quantum-Si in accordance with Nasdaq Listing Rule 5635(c)(4). The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Quantum-Si
Achieves First Quarterly Revenue Over $1 Million Completes Capital Raises of $86 Million Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced financial results for the fourth quarter and full year ended December 31, 2024. Press Release Highlights Reported revenue of $1.2 million for the fourth quarter of 2024 and $3.1 million for the full year 2024 (representing a 183% full year-over-year growth) Raised capital of over $86 million between the fourth quarter of 2024 and first week of 2025 (extending cash runway into the second half of 2027) Announced the launch of Platinum® Pro in January 2025, with shipp
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced that it will report financial results for the fourth quarter and full year 2024 on Monday, March 3, 2025. Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will host a conference call to discuss financial results and provide a business update on the same day at 4:30 PM ET. Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Quantum-Si website under Events and Presentations. Alternatively, individuals can register here to receive a dial-in numbe
Sales Pipeline is Accelerating and New Kits Remain on Track for Q4 Launch Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced financial results for the third quarter ended September 30, 2024. Press Release Highlights Reported revenue of $787,000 for the third quarter of 2024 Announced that Liberate Bio has integrated Platinum® Next-Generation Sequencing into their platform for developing novel gene therapies with improved targeting capabilities Announced appointments of industry veteran Todd Bennett as Chief Commercial Officer ("CCO"), John Vieceli, Ph.D. as Chief Product Officer and Lindsay Thompson as C
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
SC 13D/A - Quantum-Si Inc (0001816431) (Subject)
SC 13G/A - Quantum-Si Inc (0001816431) (Subject)
SC 13G - Quantum-Si Inc (0001816431) (Subject)
Alliance Global Partners initiated coverage of Quantum-Si with a rating of Buy and set a new price target of $3.75
H.C. Wainwright initiated coverage of Quantum-Si with a rating of Buy and set a new price target of $3.00
Canaccord Genuity downgraded Quantum-Si from Buy to Hold and set a new price target of $2.00 from $3.50 previously
DEFA14A - Quantum-Si Inc (0001816431) (Filer)
DEF 14A - Quantum-Si Inc (0001816431) (Filer)
S-8 - Quantum-Si Inc (0001816431) (Filer)
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced the appointment of Charles ("Chuck") Kummeth to the role of independent Chairman of the Board, effective May 27, 2024. Mr. Kummeth has over 35 years of leadership experience in Life Sciences most recently as President and CEO of Bio-Techne. During Mr. Kummeth's tenure at Bio-Techne, he oversaw tremendous growth across all aspects of the business including annual revenue growth from $300M to over $1.1B, growth in the employee base from 800 to over 3,000, and the successful execution of 19 acquisitions, all while maintaining a 35% or better EBITDA level. Under Mr. Ku
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced the appointment of Paula Dowdy, a senior executive with more than 35 years of experience across life sciences, enterprise software, and technology industries, to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321183506/en/Paula Dowdy (Photo: Business Wire) Ms. Dowdy currently serves on the Board of Directors for SPT Labtech, a world leading lab automation tools company based in the UK and is an advisor at EQT Life Sciences, one of Europe's leading investors targeting innovative
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced that it has entered into an agreement with a new distributor who will make the company's protein sequencing instrument, Platinum® available for the first time in Japan. TOMY Digital Biology Co., Ltd., a renowned importer and distributor with a rich history dating back to the 1950s, will distribute Quantum-Si's next-generation protein sequencer™ and associated consumables throughout Japan. "Working with Quantum-Si marks a pivotal moment for TOMY Digital Biology, aligning with our commitment to advancing life sciences. We're poised to empower Japanese researchers wit
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)